Concepedia

Author

Toshihiko Matsumoto

Himeji Red Cross HospitalORCID

Also Known As

T. Matsumoto, TOSHIHIKO MATSUMOTO, Toshihiko MATSUMOTO, Toshihiko Matsumoto

116

Publications

609

Citations

10

H-Index

24

Concepts

All Affiliations

Himeji Red Cross HospitalShikoku Cancer CenterKobe City Medical Center General HospitalShizuoka Cancer CenterOkayama University
TM

About

Toshihiko Matsumoto is an author at Himeji Red Cross Hospital specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

217

2

Health Sciences

2

2

25

3

Anatomy

1

1

15

4

Immunology

1

1

21

5

Kinesiology

1

1

15

Toshihiko Matsumoto

×

12

Publications

430

Citations

10

H-Index

YearCitations

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

Yasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki,

The Lancet Oncology

2017

171

Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

Hironaga Satake, Takeshi Kato, Koji Oba,

The Oncologist

2020

61

Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients

Hideomi Yamashita, Keiichi Jingu, Yuzuru Niibe,

Radiation Oncology

2017

41

Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study

Keiichi Jingu, Yuzuru Niibe, Hideomi Yamashita,

Radiation Oncology

2017

27

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Tatsuki Ikoma, Mototsugu Shimokawa, Masahito Kotaka,

BMC Cancer

2021

25

Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab

Tatsuki Ikoma, Mototsugu Shimokawa, Toshihiko Matsumoto,

Cancer Immunology Immunotherapy

2022

21

FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure

Toshihiko Matsumoto, Yusuke Kurioka, Ukyo Okazaki,

Pancreas

2020

18

Analysis of Prognostic Factors in Pancreatic Metastases

Takashi Ito, Ryoji Takada, Shunsuke Omoto,

Pancreas

2018

16

Handedness and laterality of the viscera

Toshihiko Matsumoto, Norikazu Kuriya, Tadaomi Akagi,

Neurology

1997

15

Maximum standardized uptake value in 18F-fluoro-2-deoxyglucose positron emission tomography is associated with advanced tumor factors in esophageal cancer

Takeshi Kajiwara, Yoichi Hiasa, Tomohiro Nishina,

Molecular and Clinical Oncology

2014

15

Page 1